HC Wainwright Reaffirms "Buy" Rating for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright's target price points to a potential upside of 197.62% from the company's previous close.

Separately, StockNews.com raised shares of Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday.

Syros Pharmaceuticals Trading Down 5.8 %

Shares of Syros Pharmaceuticals stock traded down $0.31 during trading hours on Monday, hitting $5.04. The company's stock had a trading volume of 355,438 shares, compared to its average volume of 201,428. Syros Pharmaceuticals has a 1-year low of $2.09 and a 1-year high of $8.17. The business has a fifty day moving average of $6.80 and a 200 day moving average of $5.09. The company has a market capitalization of $133.31 million, a PE ratio of -0.88 and a beta of 1.75. The company has a quick ratio of 3.95, a current ratio of 3.95 and a debt-to-equity ratio of 2.07.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in SYRS. Blue Owl Capital Holdings LP acquired a new stake in Syros Pharmaceuticals during the 4th quarter valued at $11,632,000. Point72 Asset Management L.P. acquired a new stake in Syros Pharmaceuticals during the 4th quarter valued at $11,465,000. Renaissance Technologies LLC acquired a new stake in Syros Pharmaceuticals during the 1st quarter valued at $975,000. Bain Capital Life Sciences Investors LLC grew its holdings in Syros Pharmaceuticals by 29.4% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 2,749,808 shares of the company's stock valued at $21,421,000 after purchasing an additional 625,114 shares in the last quarter. Finally, CHI Advisors LLC grew its holdings in Syros Pharmaceuticals by 69.3% during the 3rd quarter. CHI Advisors LLC now owns 1,299,359 shares of the company's stock valued at $5,119,000 after purchasing an additional 531,914 shares in the last quarter. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.